Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 4/20 | 0.57 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.57 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.57 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.57 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.57 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.57 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.57 |
| ▸ | AKR1C3 | P42330 | 14/20 | 0.55 |
| ▸ | AKR1C2 | P52895 | 14/20 | 0.55 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.39 |
| ▸ | AKR1C4 | P17516 | 2/20 | 0.39 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1203030 | 0.93 | APP (0.58) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL3956714 | 0.92 | APP (0.52) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1202471 | 0.91 | APP (0.58) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1202524 | 0.88 | APP (0.54) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1203229 | 0.88 | PSEN1 (0.64) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1203093 | 0.87 | AKR1C3 (0.49) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL3961691 | 0.86 | APP (0.53) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1201392 | 0.85 | AKR1C3 (0.60) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1202598 | 0.85 | APP (0.52) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1202184 | 0.84 | APP (0.51) | APPPSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140187786-A1 | 1,3,4-TRISUBSTITUTED BENZENES | ENVIVO PHARMACEUTICALS, INC. (US) | 2014-07-03 | — | — | US | disclosed |
| US-20110040094-A1 | 1,3,4-TRISUBSTITUTED BENZENES | ENVIVO PHARMACEUTICALS, INC. (US) | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110040094-A1 | 1,3,4-TRISUBSTITUTED BENZENES | BACE1, BACE2, PSEN1 | APP 4/4885PSEN1 3/4885PSEN2 5/4885 |
| US-20140187786-A1 | 1,3,4-TRISUBSTITUTED BENZENES | BACE1, BACE2, PSEN1 | APP 4/4885PSEN1 3/4885PSEN2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.